Drug Metabolism and Pharmacokinetics · 2011 · 80 citations · 11 references
PharmacyPharmacokineticsPharmacologyClinical PharmacologyMonoclonal AntibodiesPharmacokinetic ModelingAntibody PharmacokineticsModel BuildingModel EvaluationPharmacokinetics Of Monoclonal AntibodiesPopulation Pharmacokinetic ModelingTherapeutic Monoclonal AntibodiesAllometric Scaling In PharmacokineticsAnimal-to-human Pharmacokinetic TranslationConcentration-time Data AnalysisModel Validation In PharmacokineticsPharmacokinetic CalculationsPharmacokinetic Model IdentificationScaling Across Species
Interspecies allometric scaling is a useful tool for calculating human pharmacokinetic (PK) parameters from data in animals. In this study, in order to determine the scaling exponent in a simple allometric equation that can predict human clearance (CL) and distribution volume at steady state (Vss) of monoclonal antibodies (mAbs) from monkey data alone, PK data of 24 mAbs were collected and analyzed according to the types of targeted antigens (soluble or membrane-bound antigens). Based on the observed PK data in humans (at clinical doses) and monkeys (at >1 mg/kg), where the PK is expected to be linear, the mean scaling exponents in the allometric equation for CL and Vss, respectively, against body weight were calculated to be 0.79 and 1.12 [95% confidence intervals (CIs): 0.69-0.89 and 0.96-1.28] for soluble antigens, and 0.96 and 1.00 (95% CIs: 0.83-1.09 and 0.87-1.13) for membrane-bound antigens. Using these exponents and monkey PK data (at >1 mg/kg) alone, both human CL and Vss of mAbs can be predicted with reasonable accuracy, i.e., within 2-fold of the observed values. Compared with traditional allometric scaling using PK data from three or more preclinical species, this approach is simple, quick, resource-saving, and useful in drug discovery and development.
11
Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data
Rong Deng, Suhasini Iyer, Frank‐Peter Theil et al. · mAbs · 2011 · 283 citations · Full text